Navigation Links
Patient Advocate Foundation Receives Significant Support to Aid Non-Squamous Non-Small Cell Lung Cancer Patients through the Co-Pay Relief Program
Date:8/20/2012

HAMPTON, Va., Aug. 20, 2012 /PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) is pleased to announce the receipt of a generous contribution that will have direct and immediate impact by allowing PAF to continue support to patients suffering with non-squamous non-small cell lung cancer (NSCLC) within its Co-Pay Relief Program (CPR). PAF's Co-Pay Relief Program provides direct financial support for pharmaceutical co-payments to insured patients, including Medicare Part D beneficiaries, who financially and medically qualify, significantly reducing the financial burden associated with high medication costs. 

PAF is a national non-profit organization that provides sustained case management services to patients who are facing healthcare access issues as a result of their diagnosis of a chronic, life threatening or debilitating illnesses.  Since PAF's creation of the Co-Pay Relief division in April 2004, CPR has distributed more than $180 million in assistance to more than 86,000 patients who were unable to afford their pharmaceutical co-payments, thus ensuring better access to prescribed medications. Last year, the inaugural year for this disease fund within CPR, nearly 3,000 lung cancer patients suffering from this disease received funds to directly pay for their pharmaceutical co-payments.

"A debilitating or life-threatening diagnosis can be the most overwhelming experience a person may ever face in his or her lifetime. Coupled with high-cost pharmaceutical co-pay expenses, the journey can become significantly more challenging to manage," said Nancy Davenport-Ennis, founder and CEO of PAF. "Patient Advocate Foundation created the Co-Pay Relief Program in 2004 after receiving an increased number of patients seeking co-pay assistance for pharmaceutical drugs, so we are particularly pleased to be able to continue this assistance to lung cancer patients."

Globally, lung cancer is the most common form of cancer and the biggest killer, causing 1.3 million cancer deaths annually.  About 85 – 90 percent of all lung cancers are NSCLC. The liver, bones and brain are potential targets if the cancerous cells enter the bloodstream.

In FY 22011/2012, PAF's Co-Pay Relief Program assisted 36,993 patients, a dramatic 168.4 percent increase from FY 2010/2011, and provided approximately $39 million in co-payment support to patients across 19 diseases categories to help alleviate the financial burden associated with out-of-pocket pharmaceutical co-payments. 

About the Patient Advocate Foundation (PAF) Co-Pay Relief Program (CPR) 
The Co-Pay Relief Program provides direct financial support for pharmaceutical co-payments to insured patients who financially and medically qualify.  The program offers innovative technology tools for patients, providers and pharmacy representatives including 24 hour web based application portals, electronic signature, document upload and bar code fax routing capabilities, increasing the speed with which an approval can be granted and expenditure can be paid.  Keeping with Patient Advocate Foundation's emphasis on excellent patient service, the program also offers individualized service to all patients through the use of call counselors; personally guiding them through the enrollment process.  For more information or to contact the Co-Pay Relief program visit http://www.copays.org.

About Patient Advocate Foundation 
PAF is a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of financial stability relative to their diagnosis of chronic, life threatening or debilitating disease.  Patient Advocate Foundation has been consistently rated as a 4-star "exceptional" charity by Charity Navigator, the foremost independent evaluator of charities in the United States.   For more information about Patient Advocate Foundation, please visit www.patientadvocate.org/.


'/>"/>
SOURCE Patient Advocate Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
2. Healthcare Expense Management Leader Patientco Receives $3.75M in funding led by BlueCross BlueShield Venture Partners and Sandbox Industries
3. Express Scripts Launches Virtual Coaching To Help Patients Better Understand Therapy
4. Adverse Events Caused by Urinary Catheterization Endanger Patients Health Costing the US Health Care System Billions
5. UCLA Uses New Device To Replace Aortic Valve In Patients Who Cant Have Open-Heart Surgery
6. Golden Seeds Invests In DxUpClose, Disruptive Technology That Performs An Antibiotic Sensitivity Test At The Patients Bedside In Less Than An Hour
7. med fusion Partners with Theranostics Health to Advance Personalized Medicine for Patients with Cancer
8. TeleManager Changes Pharmacy-Patient Communication with iRefill Connect Suite
9. Meritage Pharma Initiates Clinical Trial of Oral Budesonide Suspension for Adolescent and Adult Patients with Eosinophilic Esophagitis
10. Patient Safety Technologies Reports Second Quarter 2012 Results
11. Wound Care Management Market to 2018 - Advanced Wound Care Modalities and an Expanding Patient Base Create Significant Growth Opportunities in Emerging Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):